Christopher W. Ryan

9.5k total citations · 2 hit papers
165 papers, 5.9k citations indexed

About

Christopher W. Ryan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Christopher W. Ryan has authored 165 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Christopher W. Ryan's work include Renal cell carcinoma treatment (37 papers), Sarcoma Diagnosis and Treatment (32 papers) and Prostate Cancer Treatment and Research (30 papers). Christopher W. Ryan is often cited by papers focused on Renal cell carcinoma treatment (37 papers), Sarcoma Diagnosis and Treatment (32 papers) and Prostate Cancer Treatment and Research (30 papers). Christopher W. Ryan collaborates with scholars based in United States, Canada and United Kingdom. Christopher W. Ryan's co-authors include Tomasz M. Beer, Margaret von Mehren, George D. Demetri, Cathryn Rankin, Ernest C. Borden, Charles D. Blanke, Vivien Bramwell, Walter M. Stadler, Michael C. Heinrich and Robert S. Benjamin and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher W. Ryan

157 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 768 citations Charles D. Blanke, Christopher W. Ryan et al. Journal of Clinical Oncology profile →
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

2008 436 citations Christopher W. Ryan, Charles D. Blanke et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher W. Ryan United States	38	3.7k	1.9k	1.5k	1.2k	1.1k	165	5.9k
Maria A. Pantaleo Italy	33	1.8k 0.5×	1.0k 0.5×	914 0.6×	1.2k 1.0×	930 0.9×	217	4.0k
Hidetaka Yamamoto Japan	42	2.7k 0.7×	2.1k 1.1×	1.6k 1.0×	780 0.6×	1.7k 1.6×	336	6.9k
Kiyokazu Nakajima Japan	48	3.4k 0.9×	1.8k 0.9×	1.8k 1.2×	1.5k 1.2×	3.9k 3.7×	407	7.8k
Carol J. Swallow Canada	42	2.8k 0.8×	2.6k 1.3×	1.2k 0.8×	686 0.6×	2.1k 2.0×	168	6.1k
Angela Greco Italy	43	1.3k 0.3×	1.9k 1.0×	3.2k 2.1×	467 0.4×	590 0.6×	120	6.3k
Paul M. Schneider Germany	45	3.4k 0.9×	1.9k 1.0×	3.7k 2.5×	593 0.5×	3.0k 2.8×	198	9.0k
Sumiya Ishigami Japan	43	2.3k 0.6×	3.0k 1.6×	1.6k 1.0×	621 0.5×	2.0k 1.9×	240	6.4k
Shoji Natsugoe Japan	43	3.2k 0.9×	2.9k 1.5×	1.7k 1.1×	855 0.7×	2.8k 2.6×	307	7.4k
Tomoyuki Kato Japan	43	2.0k 0.6×	2.6k 1.4×	1.1k 0.7×	683 0.6×	2.3k 2.2×	211	5.5k
Giovanni Grignani Italy	38	2.9k 0.8×	2.5k 1.3×	931 0.6×	233 0.2×	662 0.6×	231	5.5k

Countries citing papers authored by Christopher W. Ryan

Since Specialization

Citations

This map shows the geographic impact of Christopher W. Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher W. Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher W. Ryan more than expected).

Fields of papers citing papers by Christopher W. Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher W. Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher W. Ryan. The network helps show where Christopher W. Ryan may publish in the future.

Co-authorship network of co-authors of Christopher W. Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher W. Ryan. A scholar is included among the top collaborators of Christopher W. Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher W. Ryan. Christopher W. Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2025). A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. 45(8). 976–986.

Wagner, Andrew J., William D. Tap, Sebastian Bauer, et al.. (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. The Oncologist. 30(7). 1 indexed citations

Davis, Lara E., Emile Latour, Kevin D. Nusser, et al.. (2025). Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study. Clinical Cancer Research. 31(13). 2599–2607. 1 indexed citations

Bui, Nam Q., Vineet Kwatra, Christopher W. Ryan, et al.. (2024). Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis.. Journal of Clinical Oncology. 42(16_suppl). 11555–11555. 2 indexed citations

Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2024). Abstract CT262: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11). Cancer Research. 84(7_Supplement). CT262–CT262.

Jonasch, Eric, Bradley A. McGregor, Pavlos Msaouel, et al.. (2024). 1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study. Annals of Oncology. 35. S1011–S1012. 4 indexed citations

Desai, Jayesh, Andrew J. Wagner, Marilena Cesari, et al.. (2024). A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. Cancer. 131(1). e35634–e35634. 5 indexed citations

Patel, Sandip Pravin, Megan Othus, Young Kwang Chae, et al.. (2023). A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clinical Cancer Research. 30(1). 33–38. 15 indexed citations

Ryan, Christopher W., Catherine M. Tangen, Elisabeth I. Heath, et al.. (2023). Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. 402(10407). 1043–1051. 21 indexed citations

10.

Rogers, Richard E. L., et al.. (2022). Dietary Patterns Suggest West Virginia Bobcats Are Generalist Carnivores. Journal of Fish and Wildlife Management. 13(2). 447–459. 3 indexed citations

11.

Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations

12.

Cheng, Larry C., Changhui Xue, Christopher W. Ryan, et al.. (2021). Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Cell Reports Medicine. 2(5). 100267–100267. 8 indexed citations

13.

Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, et al.. (2019). Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology. 37(16). 1424–1431. 174 indexed citations

14.

Armstrong, Andrew J., Susan Halabi, Tim Eisen, et al.. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. The Lancet Oncology. 17(3). 378–388. 311 indexed citations

15.

Powles, T.B., Bernard Escudier, Paul de Souza, et al.. (2016). Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. Annals of Oncology. 27. vi284–vi284. 1 indexed citations

16.

Bukowski, Ronald M., Walter M. Stadler, David F. McDermott, et al.. (2010). Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology. 78(5-6). 340–347. 33 indexed citations

17.

Ross, Robert W., Tomasz M. Beer, Susanna Jacobus, et al.. (2007). A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel. Cancer. 112(3). 521–526. 85 indexed citations

18.

Beer, Tomasz M., Milind Javle, Christopher W. Ryan, et al.. (2006). Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemotherapy and Pharmacology. 59(5). 581–587. 41 indexed citations

19.

Ryan, Christopher W. & Michael R. Vaughan. (2004). Den Characteristics of Black Bears in Southwestern Virginia. Southeastern Naturalist. 3(4). 659–668. 8 indexed citations

20.

Wu, Peter, et al.. (2003). Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 134(4). 656–665. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact